Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review

March 2021 | 48 pages | ID: A6E4C10F97FEN
GlobalData

Abstracts

Vaxart Inc (VXRT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

• Business description – A detailed description of the company’s operations and business divisions.
• Corporate strategy – Analyst’s summarization of the company’s business strategy.
• SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
• Company history – Progression of key events associated with the company.
• Major products and services – A list of major products, services and brands of the company.
• Key competitors – A list of key competitors to the company.
• Key employees – A list of the key executives of the company.
• Executive biographies – A brief summary of the executives’ employment history.
• Key operational heads – A list of personnel heading key departments/functions.
• Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
• Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
• Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Vaxart Inc (Vaxart), formerly Aviragen Therapeutics Inc, is a clinical-stage pharmaceutical company that develops oral recombinant vaccines based on its proprietary oral vaccine platform, which uses state-of-the-art recombinant technology. The platform enables the company to develop oral versions of currently available vaccines, and design recombinant vaccines for new indications. Vaxart is developing prophylactic vaccine candidates for a range of infectious diseases, including norovirus infection, seasonal influenza, respiratory syncytial virus (RSV) infection, and coronavirus (COVID-19) disease. The company is also developing a therapeutic immune-oncology vaccine, which targets cervical cancer, and dysplasia caused by human papillomavirus (HPV). Vaxart is headquartered in San Francisco, California, the US.

Vaxart Inc Key Recent Developments

Feb 25,2021: Vaxart provides business update and reports fourth quarter and full year 2020 financial results
Jan 28,2021: Vaxart announces resignation of Steven Boyd and Keith Maher
Nov 12,2020: Vaxart reports third quarter 2020 financial results and provides business update
Oct 07,2020: Centaur Biopharmaceutical services announces expansion of manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
Sep 25,2020: VAXART investigation initiated by Former Louisiana Attorney General: Kahn Swick & Foti investigates the officers and directors of Vaxart - VXRT

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

• The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

• The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

• Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.

• Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

• Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Vaxart Inc - Key Facts
Vaxart Inc - Key Employees
Vaxart Inc - Key Employee Biographies
Vaxart Inc - Major Products and Services
Vaxart Inc - History
Vaxart Inc - Company Statement
Vaxart Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

SECTION 2 – COMPANY ANALYSIS

Company Overview
Vaxart Inc - Business Description
Vaxart Inc - Corporate Strategy
Vaxart Inc - SWOT Analysis
SWOT Analysis - Overview
Vaxart Inc - Strengths
Vaxart Inc - Weaknesses
Vaxart Inc - Opportunities
Vaxart Inc - Threats
Vaxart Inc - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES

Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Vaxart Inc, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Feb 25, 2021: Vaxart provides business update and reports fourth quarter and full year 2020 financial results
Jan 28, 2021: Vaxart announces resignation of Steven Boyd and Keith Maher
Nov 12, 2020: Vaxart reports third quarter 2020 financial results and provides business update
Oct 07, 2020: Centaur Biopharmaceutical services announces expansion of manufacturing agreement with Vaxart for COVID-19 and other vaccine candidates
Sep 25, 2020: VAXART investigation initiated by Former Louisiana Attorney General: Kahn Swick & Foti investigates the officers and directors of Vaxart - VXRT
Aug 27, 2020: Vaxart appoints Karen J. Wilson to its Board of Directors
Aug 06, 2020: Vaxart announces second quarter 2020 results
Jul 16, 2020: Norovirus gastroenteritis costs an estimated $10.6 Billion each year in the United States
Jul 13, 2020: Second Virus Wave fears create growing demand for testing, treatments and vaccine candidates
Jun 25, 2020: Vaxart signs Memorandum of Understanding with Attwill Medical Solutions Sterilflow

SECTION 6 – APPENDIX

Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Vaxart Inc, Key Facts
Vaxart Inc, Key Employees
Vaxart Inc, Key Employee Biographies
Vaxart Inc, Major Products and Services
Vaxart Inc, History
Vaxart Inc, Subsidiaries
Vaxart Inc, Key Competitors
Vaxart Inc, Annual Ratios
Vaxart Inc, Annual Ratios (Cont...1)
Vaxart Inc, Interim Ratios
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Vaxart Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Vaxart Inc, Performance Chart (2016 - 2020)
Vaxart Inc, Ratio Charts
Vaxart Inc, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Vaxart Inc, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021